Safety and efficacy of the combination of sonidegib and ruxolitinib in myelofibrosis: a phase 1b/2 dose-finding study

Although data from a phase 1b/2 dose-finding study of sonidegib/ruxolitinib therapy among JAK inhibitor-naïve patients with myelofibrosis demonstrated that the combination is well tolerated, only a modest overall benefit was seen compared with single-agent ruxolitinib. By weeks 24 and 48, 44.4% and 29.6% patients, respectively, experienced a ≥35% reduction in spleen volume, and 42.0% and 26.0% patients, respectively, experienced a ≥50% reduction in Myelofibrosis Symptom Assessment Form total symptom score.